Utility of adjunctive macrolide therapy in treatment of children with asthma: a systematic review and meta-analysis

Anar Mikailov1
Ilona Kane2
Stephen C Aronoff3
Raemma Luck3,†
Michael T DelVecchio3
1Beth Israel Deaconess Medical Center, Boston, MA, 2St Christopher’s Hospital for Children, Philadelphia, PA, 3Department of Pediatrics, Temple University School of Medicine, Philadelphia, PA, USA
†Raemma Luck is now deceased

Background: The purpose of this study was to investigate macrolides as an adjunct to an asthma controller regimen in children with asthma.

Methods: Prospective clinical trials of macrolide therapy in children with asthma using outcome measures of change in forced expiratory volume in one second (FEV1) and/or oral corticosteroid requirement were searched for in PubMed up to December 2009. The reference lists of studies were also included in the analysis, as well as those listed in published meta-analyses.

Results: The literature search yielded 116 studies, six of which were included in this meta-analysis. The change in FEV1 from baseline with adjunctive use of macrolide therapy in all children was not significant (0.25% predicted; 95% confidence interval [CI] −0.37, 0.86 predicted, \( P = 0.43 \)); however, the change in FEV1 among children receiving daily oral corticosteroids was significant (3.89% predicted; 95% CI −0.01, 7.79, \( P = 0.05 \)). Addition of macrolide therapy to the treatment of children with oral corticosteroid-dependent asthma resulted in a statistically significant decrease in daily corticosteroid dosage (−3.45 mg/day; 95% CI −5.79, −1.09 mg/day, \( P = 0.004 \)). This reduction in daily corticosteroid dosage was directly proportional to the duration of macrolide therapy (−0.17 mg methylprednisolone per week of macrolide therapy; 95% CI −0.33, −0.021, \( P = 0.025 \)).

Conclusion: Addition of macrolides to the treatment regimen of children with oral corticosteroid-dependent asthma improves FEV1, and decreases the daily dosage of corticosteroids required for control in these children. The degree of dose reduction is directly related to the duration of macrolide therapy. Additional large, randomized, placebo-controlled trials of adjunctive macrolide use in children with oral corticosteroid-dependent asthma are required to verify this observation.

Keywords: chronic asthma, macrolides, corticosteroid sparing

Introduction

Asthma is a respiratory disease characterized by airway inflammation, airway hyper-responsiveness, and resultant reversible airway obstruction. Approximately 12% of children are afflicted with the disease, and it is the most common cause of childhood hospitalizations.1 Asthma therapy revolves around managing respiratory symptoms, airway inflammation, and airway hyper-responsiveness.1 Commonly used agents include bronchodilators and inhaled corticosteroids.1 Patients with more severe asthma require daily oral steroid therapy and occasionally immunosuppressive agents.

When managing chronic asthma in children, any side effects of the treatment modality become important. Recently, long-acting beta-agonists have received a black-box warning for monotherapy.2 Furthermore, corticosteroids are notorious for a wide range
of detrimental effects, such as growth retardation, decreased bone mineral density, skin thinning, cataracts, glucose intolerance, hypertension, central obesity, and suppression of the hypothalamic-pituitary-adrenal axis.2,3 The 2008 Childhood Asthma Management Program study of long-term oral corticosteroid use in children with asthma found a dose-dependent increase in risk of osteopenia and a decrease in bone mineral accrual.4 Significant improvement in chronic treatment of asthma in children is necessary to address the morbidity and mortality associated with current approaches.

Antibiotics, especially macrolides, have been extensively investigated as a potential treatment in asthma, chronic obstructive pulmonary disease, and cystic fibrosis.5,6 Although many clinicians prescribe antibiotics in the setting of chronic asthma and its exacerbations, current national guidelines discourage such use.7,8 Nevertheless, due to their anti-inflammatory and antibacterial effects, macrolides show great potential as an adjunct treatment for asthma.9 Since the late 1950s, macrolide therapy has been recognized to improve outcomes in children and adults with asthma.10–16 In 1970, Itkin and Menzel17 reported a steroid-sparing effect of macrolides. In agreement with Itkin and Menzel, in a randomized controlled trial designed to investigate the effects of macrolide therapy on childhood asthma, Kamada et al14 showed a statistically significant steroid-sparing effect and an improvement in forced expiratory volume in one second (FEV₁). In contrast, a Cochrane meta-analysis of macrolide use for chronic asthma in children and adults showed insufficient evidence to support or refute use of macrolides.18 The present systematic review and meta-analysis was undertaken to determine the effect of macrolide therapy on management of asthma in children.

Materials and methods

We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria when performing this study. The MEDLINE and EBM (Evidence-Based Medicine) Reviews/Cochrane Central Register of Controlled Trials databases were searched using both the Ovid and PubMed search engines, covering the period from 1950 to 2009. Search terms included “macrolides”, “asthma”, and “children”, with a focus on the subtopics “treatment” and “therapy”. A review of the bibliographies of selected references was also performed.

Study selection and data extraction

Inclusion criteria were a clinical diagnosis of asthma, age 2–18 years, a macrolide antibiotic used as an adjunctive controller, oral corticosteroid use with dosage determined before and after initiation of macrolide therapy, and FEV₁ as percent predicted measured before and after initiation of macrolide therapy. Studies were excluded if presented as a review article or meta-analysis or if patients with chronic respiratory conditions other than asthma, such as cystic fibrosis, were included. The studies recovered from the database searches were screened by title, abstract, and article type. The methods sections from those studies that survived the initial cull were blindly reviewed for compliance with our inclusion criteria by MD and RL.

Statistical analysis

Differences in mean FEV₁ and daily oral dosage of corticosteroids before and after therapy were computed for each study and for all studies combined. Heterogeneity among studies was determined by Cochrane’s Q statistic and by calculating the resulting P value. A P < 0.05 was suggestive of significant heterogeneity. If was calculated to determine the extent of heterogeneity across studies. In cases where heterogeneity was significant, the studies were combined using the random-effects model. The effect of duration of macrolide therapy on daily oral corticosteroid dosage was determined by meta-regression; a P value < 0.05 for the slope of the regression line was considered to be statistically significant. All analyses were performed with meta-analysis software (Comprehensive Meta-Analysis version 2.0, Biostat Inc, Englewood, NJ, http://www.meta-analysis.com).

Results

Literature flow

The Ovid, MEDLINE, and PubMed searches yielded 116 references for review. From the 116 titles and abstracts, 22 references were excluded. The full text of 94 references was then reviewed and another 79 references were excluded, resulting in a total of 15 studies that were then reviewed by blinded team members (MD and RL). Of the 15 references, six11–16 were included in the final report (Figure 1, Table 1). Because only two11,14 of the six included studies used a placebo group, the present study considered the pre and post-treatment groups only to maintain homogeneity.

The total pediatric sample size of the combined studies was 69. Five prospective studies11–15 were identified and included in the analysis of macrolide therapy and FEV₁ change (Table 2, Figure 2). Four studies11–16 were included in the analysis of macrolide therapy and oral corticosteroid dose change (Table 3, Figure 3), three of which were included in the subgroup meta-regression analysis.13–15
Publications included in analysis of OCS dose change and macrolide therapy (n = 4)

Publications included in analysis of FEV<sub>1</sub> change and macrolide therapy (n = 5)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications included in subgroup meta-regression analysis (n = 3)

Publications potentially suitable for inclusion in meta-analysis (n = 94)

Publications included in analysis of OCS dose change and macrolide therapy (n = 4)

Publications included in analysis of FEV<sub>1</sub> change and macrolide therapy (n = 5)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications included in subgroup meta-regression analysis (n = 3)

Publications included in meta-analyses (n = 6)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications included in subgroup meta-regression analysis (n = 3)

Publications included in analysis of OCS dose change and macrolide therapy (n = 4)

Publications included in analysis of FEV<sub>1</sub> change and macrolide therapy (n = 5)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications included in subgroup meta-regression analysis (n = 3)

Publications included in analysis of OCS dose change and macrolide therapy (n = 4)

Publications included in analysis of FEV<sub>1</sub> change and macrolide therapy (n = 5)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications excluded from OCS change analysis, because patients were not OCS-dependent (n = 2)

Publications excluded from FEV<sub>1</sub> change analysis, because not all patients had final FEV<sub>1</sub> values (n = 1)

Publications excluded from meta-regression analysis, because duration of therapy was not discrete (n = 1)

Publications included in subgroup meta-regression analysis (n = 3)
Table 2 Changes in FEV1 with addition of macrolide

<table>
<thead>
<tr>
<th>Study</th>
<th>OCS use</th>
<th>Macrolide</th>
<th>n</th>
<th>Duration of macrolide treatment</th>
<th>Pretreatment FEV1 ± SEM</th>
<th>Post treatment FEV1 ± SEM</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piacentini et al11</td>
<td>No</td>
<td>Azithromycin</td>
<td>8</td>
<td>8 weeks</td>
<td>73.5 ± 12.9</td>
<td>74.62 ± 9.76</td>
<td>0.84</td>
</tr>
<tr>
<td>Shimizu et al12</td>
<td>No</td>
<td>Roxithromycin</td>
<td>12</td>
<td>8 weeks</td>
<td>81.5 ± 2.2</td>
<td>82.0 ± 3.0</td>
<td>0.64</td>
</tr>
<tr>
<td>Zeiger et al13</td>
<td>Yes</td>
<td>TAO</td>
<td>3</td>
<td>6 weeks</td>
<td>67.3 ± 12.4</td>
<td>100 ± 6.0</td>
<td>0.01</td>
</tr>
<tr>
<td>Kamada et al14</td>
<td>Yes</td>
<td>TAO</td>
<td>6</td>
<td>12 weeks</td>
<td>80.4 ± 6.5</td>
<td>73.6 ± 6.3</td>
<td>0.00</td>
</tr>
<tr>
<td>Eitches et al15</td>
<td>Yes</td>
<td>TAO</td>
<td>11</td>
<td>52 weeks</td>
<td>54 ± 4.8</td>
<td>97 ± 6.5</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Notes: Excluded from this analysis because post treatment FEV1 values were not recorded; *only patients from the treatment group were used in our study to maintain homogeneity as described in the results section.

Abbreviations: TAO, troleandomycin; FEV1, forced expiratory volume in one second; OCS, oral corticosteroids; SEM, standard error of the mean.

Of note, four of six11–14 studies specifically excluded patients with evidence of upper respiratory illness or viral infection. Piacentini et al reported that none of the patients in their study had clinical signs or symptoms or airway infections in the months before or during the study.11 Shimizu et al required that their subjects were free from upper respiratory tract infections for 4 weeks prior to study entry.12 Zeiger et al noted that no patients had evidence of infection at the start of the study.13 Kamada et al excluded all patients who had evidence of respiratory infection within 4 weeks of enrollment.14 Eitches et al15 and Flotte et al16 did not specify viral illness as an exclusion criterion.

FEV1 change

Table 2 presents the five studies included in the analysis of the effects of macrolide on FEV1 in children with asthma. Due to significant heterogeneity across studies ($I^2 = 89.80, Q = 39.23, P = 0.002$), the random-effects model was used. As seen in Figure 2, macrolide therapy had no impact overall on changes in FEV1. When subsets of studies were investigated, macrolide therapy failed to impact FEV1 in patients who were not oral corticosteroid-dependent (standard difference in mean = 0.15% predicted; 95% CI −0.47, 0.77, $P = 0.63$), but had a significant impact on oral corticosteroid-dependent patients (standard difference in mean = 3.89% predicted; 95% CI −0.01, 7.79, $P = 0.05$).

Change in oral corticosteroid dose

Table 3 and Figure 3 present the four studies included in the analysis of the effects of macrolide on oral corticosteroid dosing in children with asthma. The random-effects model was used due to significant heterogeneity across studies ($F = 82.49, Q = 17.14, P < 0.05$). Addition of macrolide therapy in children with oral corticosteroid-dependent...
adjuvant use of macrolides in children with asthma resulted in a statistically significant decrease in daily corticosteroid dosage (-3.45 mg/day; 95% CI: -5.79 to -1.09, P = 0.004). The effect of duration of macrolide therapy on daily oral corticosteroid dosage was determined by meta-regression. As the duration of macrolide therapy increased, the daily oral corticosteroid dosage was reduced by 0.17 mg per week (95% CI: 0.021 –0.33 mg of Methylprednisolone per week of macrolide therapy, P = 0.025).

**Discussion**

The present study found that while adjunctive macrolide therapy did not affect FEV$_1$ in children without oral corticosteroid-dependent asthma, FEV$_1$ improved in children with oral corticosteroid-dependent asthma. Moreover, among children requiring daily oral corticosteroids for control of asthma, addition of a macrolide agent decreased daily oral corticosteroid dosage requirements, and the degree of this reduction was directly proportional to duration of macrolide therapy.

While the utility of macrolide therapy in asthma has been well studied in the general population, it has been poorly studied in childhood asthma. Richeldi et al$^{16}$ reviewed randomized controlled trials of macrolide administration in patients with asthma, and identified a sample size of 398 adults from six studies, and 18 children from one study. This meta-analysis found insufficient evidence to recommend macrolide therapy in patients with chronic asthma. In particular, the authors failed to find that macrolide therapy had a significant impact on daily oral corticosteroid dosage. This last conclusion was based on two studies. Nelson et al$^{19}$ studied 75 adults and did not find a difference in daily oral corticosteroid dosage between their treatment and placebo groups. Kamada et al$^{14}$ studied 11 children, and found a statistically significant reduction in daily oral corticosteroid dosage for children receiving macrolide therapy when compared with a placebo group. The present study, which found an effect of macrolide therapy on daily oral corticosteroid dosage, included parallel and crossover clinical trials involving only children. These observations suggest that macrolide therapy may have a steroid-sparing effect in children but not in adults. Further studies are needed to resolve this issue.

Potential mechanisms of macrolide effects are likely related to modulation of inflammatory cytokines, such as interleukin (IL)-5, IL-8, and vascular endothelial growth factor (VEGF). In a prospective cohort study from 2010, Korematsu et al$^{20}$ showed a correlation between children with severe asthma and high levels of IL-8 and VEGF. Furthermore, that study showed that low-dose erythromycin

### Table 3 Changes in OCS dose with addition of macrolide

<table>
<thead>
<tr>
<th>Study</th>
<th>Macrolide</th>
<th>OCS</th>
<th>n</th>
<th>Duration of macrolide treatment (weeks)</th>
<th>Pretreatment OCS dose ± SEM (mg/day)</th>
<th>Post treatment OCS dose ± SEM (mg/day)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zeiger et al$^{13}$</td>
<td>TAO</td>
<td>MPn</td>
<td>3</td>
<td>6</td>
<td>19.3 ± 6.8</td>
<td>14.7 ± 4.7</td>
<td>0.002</td>
</tr>
<tr>
<td>Kamada et al$^{14}$</td>
<td>TAO</td>
<td>MPn</td>
<td>6$^a$</td>
<td>12</td>
<td>34.2 ± 9.6</td>
<td>4.9 ± 1.0</td>
<td>0.00</td>
</tr>
<tr>
<td>Eitches et al$^{15}$</td>
<td>TAO</td>
<td>MPn</td>
<td>10$^b$</td>
<td>52</td>
<td>19.8 ± 3.1</td>
<td>3.2 ± 0.4</td>
<td>0.00</td>
</tr>
<tr>
<td>Flootte et al$^{16}$</td>
<td>TAO</td>
<td>MPn</td>
<td>9</td>
<td>16–136$^c$</td>
<td>15.3 ± 3.04</td>
<td>1.4 ± 0.26</td>
<td>0.245</td>
</tr>
</tbody>
</table>

**Notes:** Piacentini et al and Shimizu et al are excluded because their patients were not OCS-dependent. $^a$Although there were 11 patients in the study, one patient's baseline methylprednisolone dose was described as "variable" and not included in this analysis; $^b$duration of therapy was not specified per patient; $^c$only the patients from the TAO-MPn group were used in our study to maintain homogeneity as described in the results section.$^{13} - ^{15}$ The studies included in the meta-regression analysis. Flootte et al was excluded because duration was not discretely defined for each patient.

**Abbreviations:** TAO, troleandomycin; OCS, oral corticosteroids; MPn, methylprednisolone; SEM, standard error of the mean.

---

**Figure 3** Random effects model analysis of adjunctive macrolide use and oral steroid dose change in children with asthma.

**Notes:** I$^2$ = 82.49, Q = 17.14, P < 0.05.
significantly improved clinical symptoms and decreased levels of both IL-8 and VEGF in children with severe asthma, but not in children with mild to moderate asthma.\textsuperscript{20}

In a cross-sectional controlled study performed in 2011, Lin et al\textsuperscript{21} showed that children with asthma produced significantly higher levels of IL-5 compared with children without asthma, and addition of azithromycin significantly decreased IL-5 levels in a dose-dependent fashion. In the present study, the most severely affected children, ie, those who were dependent on oral corticosteroids, saw the most benefit from macrolide therapy, a result that is likely related to the pathophysiology observed in the Korematsu et al\textsuperscript{20} study. It is unclear why children but not adults (as determined by a Cochrane review\textsuperscript{18}) show significant steroid-sparing effects from adjunctive macrolide therapy. The common saying may be appropriate here, ie, that “children are not simply young adults”.

The present study has several limitations. First, troleandomycin and methylprednisolone were used in all studies where a steroid-sparing effect was observed. Prior studies have suggested a pharmacokinetic interaction between these two agents that directly increases steroid concentrations.\textsuperscript{13,22}

It is not known whether this same effect exists between other members of the macrolide and corticosteroid classes. Another significant limitation is sample size: our aggregate data analyzed a total of 69 patients from six studies, and four of these (n = 28) were analyzed for steroid-sparing effect. Nevertheless, to the authors’ knowledge, this is the largest sample size to date to have evaluated the effect of macrolides in children with corticosteroid-dependent asthma. Further, the studies were performed many years earlier, in some cases 30 years ago, when definitions and standard of care protocols were different from those used today. Furthermore, although the improvement in FEV\textsubscript{1} was statistically significant, it may not necessarily be clinically significant, and future studies should include outcomes, such as responses to an asthma symptom questionnaire and numbers of acute care visits.

In summary, this study demonstrates that macrolides have a steroid-sparing effect in children with steroid-dependent asthma. In addition, we found a direct association between duration of macrolide therapy and magnitude of change in oral corticosteroid dosage before and after therapy. The present study supports the need for a large, randomized, placebo-controlled, crossover trial of a modern macrolide in children with steroid-dependent asthma.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
